Mu-type opioid receptor - Alpha-2A adrenergic receptor heteromer (MOR-ADRA2A heteromer)

The Mu-type opioid receptor (MOR) and Alpha-2A adrenergic receptor (ADRA2A) form functional heteromeric complexes that are primarily localized in the dorsal horn of the spinal cord and other key pain-processing regions (Vilardaga et al., 2008). This heteromerization allows for direct allosteric cross-talk, where the activation of the adrenergic receptor can significantly enhance the analgesic potency of opioid ligands (Stone et al., 1997). This synergistic interaction is the pharmacological basis for combining opioids with alpha-2 agonists like clonidine to achieve superior pain relief with lower doses, thereby potentially reducing the risk of dose-dependent side effects such as respiratory depression (Small et al., 2013). Research into bivalent ligands, such as MCC22, specifically targets this heteromer to exploit its unique signaling properties for treating chronic and neuropathic pain (Akgün et al., 2013). These complexes represent a sophisticated therapeutic target that leverages the endogenous noradrenergic modulation of the opioid system to improve the safety profile of analgesics (Jordan & Devi, 1999). Furthermore, the MOR-ADRA2A heteromer plays a role in the development of opioid tolerance, making its modulation a promising strategy for maintaining long-term efficacy in pain management (Prinster et al., 2005).

Other names

MOR-alpha2AAR heteromerMu-opioid receptor-alpha-2A-adrenergic receptor complexMOR-ADRA2A complexOpioid-adrenergic receptor heteromerOPRM1-ADRA2A heteromer

Allosteric modulation within a GPCR heteromer where the conformational change induced by a ligand at the Alpha-2A adrenergic receptor enhances the signaling efficacy or affinity of the Mu-type opioid receptor.